4DX
data caveat$3.0B5mo
4DMedical
Medical Devices · Medical imaging
XV Technology for lung ventilation imaging and analytics
Data HealthTrials1 of 1 active · stale enrollment
Cash data from Dec 2025 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$4.3M
Dec 2025 4C
Runway
5moCRITICAL
Based on Dec 2025 4C
Market Cap
$3.0B
Burn Rate
$2.6M/qtr
Dec 2025 4C
Shares Outstanding
591M
Pipeline Assets
2
Latest Insight(1)
19 Apr 2026RegulatoryGSK contract, UK clearance for CTVQ, and ASX 200 inclusion
CT:VQ™ received UKCA certification for clinical use in the United Kingdom under the regulatory oversight of the Medicines and Healthcare products Regulatory Agency (MHRA), following CE Mark certification in March 2026. This clearance allows immediate commercial deployment of CT:VQ™ across public and private healthcare providers in the UK.
MHRA·Functional lung imaging for respiratory conditions including COPD, interstitial lung disease, pulmonary embolism, and lung cancer screening·positive
3M Price
4DX.ASX$5.120+24.0% 3M
Low $3.100High $6.800
Pipeline Assets (2)
CT:VQCT lung imaging
Phase 2XV LVASLung ventilation analysis
ApprovedDiscovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Approved
CT:VQ
CT lung imaging
Capital Raises & Buybacks
5 raises
Current shares outstanding: 591M
Placement
Options
2026-03-27placement
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Short Interest
ASIC ↗as of 2026-03-27 · 4-day lag
Short position
3.11%
arrow_drop_up+3.01% over 30 reports
Shares short
17.8M
Aggregated short position data published by ASIC under the Corporations Act. T+4 reporting lag applies. Short interest ≥5% is noteworthy; ≥10% is elevated. Source: ASIC Short Selling Data
Competitive Landscape
12 competitor trialsPhase 2+ · Non-ASX
Ct Lung Imaging11 active trials
2 Ph32 Ph27 Ph1/PHASE2
Lung Ventilation Analysis1 active trial
1 Ph4
Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.
Catalysts (4)· 3 upcoming · 1 past
SpeculativeremoveMed31 May 2026
XV LVAS US reimbursement progress
UpcomingExpectedarrow_upwardHigh30 June 2026
CT:VQ Phase 2 interim results
UpcomingExpectedremoveMed30 Sept 2026
1 past catalyst
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
1/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
High93/100
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Hit 1 of 1 guided dates· rolling 2yr(limited sample)· of 4 tracked
What drove these scores · rolling 2yr
arrow_drop_down
Cash position declining — Cash balance dropped >30% over last 3 quarters
arrow_drop_up
Stable burn rate — 23% quarterly variation — consistent spend
arrow_drop_up
R&D-focused spend — 72% of opex directed to R&D
·
Phase 3+ thresholds — Burn rate variability thresholds adjusted for late-stage development
Completed catalysts
✓CT:VQ™ MHRA — GSK contract, UK clearance for CTVQ, and ASX 200 inclusion— CT:VQ™ received UKCA certification for clinical use in the United Kingdom under the regulatory oversight of the Medicines and Healthcare products Regulatory Agency (MHRA), following CE Mark certification in March 2026. This clearance allows immediate commercial deployment of CT:VQ™ across public and private healthcare providers in the UK.
On time
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
Clinical Trials(2)
1 activeClinicalTrials.gov ↗
RecruitingOBSERVATIONALEnrollment stale · 1052d
Computed Tomography of the Chest
Ventilatory and Perfusion Abnormalities in Individuals With Post-Acute Sequelae of SARS-CoV-2 Infection
Post-Acute COVID-19 · Post COVID-19 Condition · Post Viral Fatigue +1 more
18 Years – 99 Years
Primary endpoint Measures of regional lung ventilation
Announcements(13)
verified
RegulatoryPSauto_awesome
GSK contract, UK clearance for CTVQ, and ASX 200 inclusion19 Apr 2026
expand_more374KB